[go: up one dir, main page]

HN2010002074A - TIAZOLOPIRIDIN-2-ILOXI-FENILY TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS - Google Patents

TIAZOLOPIRIDIN-2-ILOXI-FENILY TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS

Info

Publication number
HN2010002074A
HN2010002074A HN2010002074A HN2010002074A HN2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A HN 2010002074 A HN2010002074 A HN 2010002074A
Authority
HN
Honduras
Prior art keywords
iloxi
tiazolopiridin
fenil
modulators
tiazolopirazin
Prior art date
Application number
HN2010002074A
Other languages
Spanish (es)
Inventor
M Bacani Genesis
Eunice Y Broggini
Christa C Cheung
Xiaohu Deng Chrovian
M Fourie Anne
Gomez Cheryl A Laurent
Aaron M Kearney Grice
M Landry-Bayle Adrienne
Lee-Dutra Alice
T Liang Jimmy
Lochner Susanne
S Mani Neelakandha
Santillan Alejsandro Jr
C Sappey Kathleen
Sepassi Kia
M Tanis Virginia
T Wickboldt Alvah
J M Wiener John
Zinser Hartmut
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HN2010002074A publication Critical patent/HN2010002074A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE TIAZOLOPIRIDIN-2-ILOXI-FENIL Y TIAZOLOPIRAZIN-2-ILOXI FENIL AMINA UTILES COMO MODULADORES DE LA LTA4 HIDROLASA(LTA4H). ESOS COMPUESTOS SE PUEDEN USAR EN COMPOSICIONES FARMACEUTICAS Y METODOS PARA LA MODULACION DE LTA4H Y PARA EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD, TRASTORNOS Y AFECCIONES MEDIADOS POR LA ACTIVIDAD DE LA LTA4 HIDROLASA.THIS INVENTION REFERS TO TIAZOLOPIRIDIN-2-ILOXI-FENIL AND THIAZOLOPIRAZIN-2-ILOXI PHENYL AMINE COMPOUNDS USED AS MODULATORS OF LTA4 HYDROLASSES (LTA4H). THOSE COMPOUNDS CAN BE USED IN PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE MODULATION OF LTA4H AND FOR THE TREATMENT OF DISEASE STATES, DISORDERS AND AFFECTIONS MEASURED BY THE ACTIVITY OF LTA4 HYDROLASE.

HN2010002074A 2008-04-11 2010-10-11 TIAZOLOPIRIDIN-2-ILOXI-FENILY TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS HN2010002074A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4434908P 2008-04-11 2008-04-11
US14912909P 2009-02-02 2009-02-02

Publications (1)

Publication Number Publication Date
HN2010002074A true HN2010002074A (en) 2012-12-03

Family

ID=41130551

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2010002074A HN2010002074A (en) 2008-04-11 2010-10-11 TIAZOLOPIRIDIN-2-ILOXI-FENILY TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS

Country Status (35)

Country Link
US (3) US7939527B2 (en)
EP (2) EP2268646B9 (en)
JP (2) JP5530423B2 (en)
KR (1) KR101228378B1 (en)
CN (1) CN102056933B (en)
AR (1) AR072353A1 (en)
AU (1) AU2009234140B2 (en)
BR (1) BRPI0911336A2 (en)
CA (1) CA2721099C (en)
CL (1) CL2009000877A1 (en)
CO (1) CO6260069A2 (en)
CY (1) CY1114628T1 (en)
DK (2) DK2268646T3 (en)
EA (1) EA018802B1 (en)
EC (1) ECSP10010558A (en)
ES (2) ES2440746T3 (en)
HN (1) HN2010002074A (en)
HR (2) HRP20131192T1 (en)
IL (2) IL208480A (en)
JO (1) JO2911B1 (en)
MX (1) MX2010011154A (en)
MY (1) MY157597A (en)
NI (1) NI201000168A (en)
NZ (2) NZ588341A (en)
PE (1) PE20091779A1 (en)
PH (1) PH12013500094B1 (en)
PL (2) PL2336125T3 (en)
PT (2) PT2336125E (en)
RS (2) RS52712B (en)
SI (2) SI2336125T1 (en)
SV (1) SV2010003694A (en)
TW (2) TWI461196B (en)
UY (1) UY31760A (en)
WO (1) WO2009126806A2 (en)
ZA (1) ZA201008054B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1976828T (en) 2005-12-29 2017-03-10 Celtaxsys Inc DIAMINE DERIVATIVES AS LEUCOTYRENE A4 HYDROLASE INHIBITORS
PT2336125E (en) * 2008-04-11 2013-03-18 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase
JP6080226B2 (en) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzodioxane for inhibiting leukotriene production in combination with other active substances
JP6080227B2 (en) * 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzodioxane for inhibiting leukotriene formation
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
ES2864862T3 (en) 2013-03-12 2021-10-14 Celltaxis Llc Leukotriene A4 hydrolase inhibition methods
CA2906086A1 (en) * 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
MX2015011677A (en) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibitors of leukotriene a4 hydrolase.
AU2019278935B2 (en) 2018-05-31 2025-02-13 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
WO2020146822A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008A (en) * 1847-03-13 Machinery for cleaning
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
US4424358A (en) 1979-01-16 1984-01-03 Delalande S.A. β-3-Amino nor-tropane compounds
FR2446823A1 (en) 1979-01-16 1980-08-14 Delalande Sa 3-Acylamino-8-arylmethyl-nortropane derivs. - useful as neuroleptic agents (NL 18.7.80)
US4329466A (en) 1979-01-16 1982-05-11 Delalande S.A. Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives
FR2476088A2 (en) 1979-01-16 1981-08-21 Delalande Sa NOVEL NOR-TROPANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US4321378A (en) 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4352802A (en) 1980-06-10 1982-10-05 Beecham Group Limited Bicyclo[3.3.1]nonyl-benzamide
ZA818221B (en) 1980-12-12 1982-10-27 Beecham Group Plc Pharmaceutical compounds
US4432983A (en) 1981-04-30 1984-02-21 Research Corporation Conformationally restricted histamine H2 -receptor antagonists containing a tropane ring
DE3137996A1 (en) * 1981-09-24 1983-04-28 Hoechst Ag, 6230 Frankfurt HETEROCYCLIC PHENYL ETHERS, METHOD FOR THE PRODUCTION THEREOF AND HERBICIDES CONTAINING THEM
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
NZ222047A (en) 1986-10-08 1991-01-29 Bristol Myers Co Quinoline - or naphthyridine - carboxylic acid anti-bacterial agents
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
JPS63170356A (en) 1986-12-30 1988-07-14 Yamanouchi Pharmaceut Co Ltd Aniline derivative and production thereof
FI91859C (en) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogue method for the preparation of an active benzothiazole derivative as an antiallergic agent
US5070094A (en) 1989-09-05 1991-12-03 G. D. Searle & Co. N-benzyltropaneamides
US5220063A (en) * 1991-05-10 1993-06-15 Hoechst Celanese Corporation Method for the preparation of arylalkanolacylamides
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
TW251287B (en) 1993-04-30 1995-07-11 Nissei Co Ltd
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
US6110994A (en) * 1996-06-14 2000-08-29 Cabot Corporation Polymeric products containing modified carbon products and methods of making and using the same
US6110944A (en) 1997-03-12 2000-08-29 G. D. Searle & Co. LTA4, hydrolase inhibitors
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6559140B2 (en) 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
FR2831884B1 (en) 2001-11-02 2003-12-26 Pf Medicament NOVEL HETEROAROMATIC AMIDE DERIVATIVES OF 3 BETA-AMINO AZABICYCLOOCTANE, PREPARATION METHOD THEREOF AND THERAPEUTIC APPLICATIONS THEREOF
EP1367481A3 (en) 2002-05-29 2008-04-09 Hitachi, Ltd. Centralized storage management method
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
SE0301373D0 (en) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AU2004247023A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
ES2313079T3 (en) 2003-07-28 2009-03-01 Janssen Pharmaceutica Nv BENZIMIDAZOL, BENZOTIAZOL, BENZOXAZOL AND ITS USE AS MODULATORS OF LTA4H.
CN101407471A (en) 2003-08-29 2009-04-15 小野药品工业株式会社 Compound capable of binding S1P receptor and pharmaceutical use thereof
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
MX2007000015A (en) 2004-06-22 2007-03-07 Schering Corp Cannabinoid receptor ligands.
GB2415818B (en) 2004-06-30 2008-12-31 Autoliv Dev Arrangement for triggering a vehicle safety device
PE20090123A1 (en) 2004-09-13 2009-03-10 Ono Pharmaceutical Co A HETEROCYCLIC DERIVATIVE CONTAINING NITROGEN AND A DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT
MX2007012235A (en) 2005-03-31 2008-03-18 Johnson & Johnson Phenyl and pyridyl lta4h modulators.
ES2277745B1 (en) 2005-06-14 2008-06-01 Laboratorios Almirall S.A. N-AMIDA DERIVATIVES OF 8-AZABICICLO /3.2.1/OCT-3-ILO AS AN ANTIGONISTS OF CCR1.
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
PT1976828T (en) * 2005-12-29 2017-03-10 Celtaxsys Inc DIAMINE DERIVATIVES AS LEUCOTYRENE A4 HYDROLASE INHIBITORS
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
ES2498043T3 (en) 2006-06-06 2014-09-24 Cornerstone Therapeutics Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
WO2008077103A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of ccr5 inhibitors
TW200906396A (en) 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
US7935725B2 (en) * 2007-10-31 2011-05-03 Janssen Pharmaceutica Nv Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
PT2336125E (en) * 2008-04-11 2013-03-18 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase

Also Published As

Publication number Publication date
ECSP10010558A (en) 2010-11-30
UY31760A (en) 2009-11-10
EP2336125A1 (en) 2011-06-22
WO2009126806A8 (en) 2010-11-18
TW201002320A (en) 2010-01-16
NZ599853A (en) 2012-08-31
WO2009126806A2 (en) 2009-10-15
EP2268646B9 (en) 2014-11-19
HRP20130278T1 (en) 2013-06-30
TWI461196B (en) 2014-11-21
US8357684B2 (en) 2013-01-22
PT2268646E (en) 2013-12-10
AU2009234140B2 (en) 2013-04-11
US7939527B2 (en) 2011-05-10
MY157597A (en) 2016-06-30
CN102056933B (en) 2014-09-17
CN102056933A (en) 2011-05-11
SI2268646T1 (en) 2013-12-31
SV2010003694A (en) 2011-03-17
IL208480A (en) 2014-11-30
US20110159563A1 (en) 2011-06-30
JP5675943B2 (en) 2015-02-25
CA2721099A1 (en) 2009-10-15
KR101228378B1 (en) 2013-01-31
DK2336125T3 (en) 2013-04-08
PT2336125E (en) 2013-03-18
HK1158208A1 (en) 2012-07-13
NZ588341A (en) 2012-06-29
SI2336125T1 (en) 2013-04-30
EA201071186A1 (en) 2011-06-30
IL226244A0 (en) 2013-06-27
JP2011516571A (en) 2011-05-26
AU2009234140A1 (en) 2009-10-15
JP5530423B2 (en) 2014-06-25
PL2268646T3 (en) 2014-02-28
BRPI0911336A2 (en) 2021-06-29
PH12013500094A1 (en) 2015-02-23
ES2400875T3 (en) 2013-04-15
CY1114628T1 (en) 2016-10-05
MX2010011154A (en) 2010-12-21
WO2009126806A3 (en) 2010-03-18
US20090258854A1 (en) 2009-10-15
AR072353A1 (en) 2010-08-25
CA2721099C (en) 2017-04-25
IL226244A (en) 2014-12-31
PH12013500094B1 (en) 2015-02-23
NI201000168A (en) 2015-05-27
ZA201008054B (en) 2012-04-25
ES2440746T3 (en) 2014-01-30
PE20091779A1 (en) 2009-11-14
KR20110013386A (en) 2011-02-09
HRP20131192T1 (en) 2014-01-17
US20110190503A1 (en) 2011-08-04
IL208480A0 (en) 2010-12-30
RS53081B (en) 2014-06-30
EP2268646A2 (en) 2011-01-05
CL2009000877A1 (en) 2009-11-27
PL2336125T3 (en) 2013-06-28
EP2268646B1 (en) 2013-10-02
CO6260069A2 (en) 2011-03-22
RS52712B (en) 2013-08-30
TW201420100A (en) 2014-06-01
DK2268646T3 (en) 2013-11-18
EP2336125B1 (en) 2013-01-09
HK1152041A1 (en) 2012-02-17
JP2014144949A (en) 2014-08-14
JO2911B1 (en) 2015-09-15
EA018802B1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
HN2010002074A (en) TIAZOLOPIRIDIN-2-ILOXI-FENILY TIAZOLOPIRAZIN-2-ILOXI-FENIL AMINAS AS MODULATORS OF LEUCOTRENE A4 HYDROLASS
CR11292A (en) COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
HN2012000973A (en) N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXYLASE INHIBITORS
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112013001613A2 (en) tricyclic compounds and methods for making and using them.
GT201300258A (en) PIRAZOLOESPIROCETONE DERIVATIVES FOR USE AS ACETIL-COA CARBOXYLASE INHIBITORS
CR20110134A (en) Compounds with spiro-tricyclic rings as beta-secretases modulators and methods of use
BR112013027774A2 (en) new compounds as protein kinase modulators
BR112012004696A2 (en) compounds and compositions as modulators of tlr activity
BR112012008004A2 (en) compounds and compositions as modulators of gpr119 activity
GEP20146033B (en) N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides usage as wnt signaling modulators
ECSP13012478A (en) HETEROCYCLIC COMPOUND AND ITS USE
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
MX351028B (en) CERTAIN ENTITIES, COMPOSITIONS AND CHEMICAL METHODS.
BR112012007747A2 (en) HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES
EA201001329A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
BRPI0808775A2 (en) compounds and compositions as modulators of gpr119 activity
EA201391390A1 (en) CYCLOPROPYLAMINES AS LSD INHIBITORS
MX379016B (en) COMPOSITIONS AND METHODS FOR TREATING GAUCHER&#39;S DISEASE.
AR081681A1 (en) METHODS AND COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF b-GALACTOCEREBROSIDASA
UY33276A (en) AMINO-OXAZINES AND AMINO-DIHYDROTIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
BR112014017673A8 (en) TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS FOR MAKING AND USING THEM
EA201001332A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA201001330A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
BRPI0820668A2 (en) 5-HALOGEN SUBSTITUTED OXINDOL DERIVATIVES AND THEIR USE TO TREAT VASOPRESSIN DEPENDENT DISEASES